The AIM B Avareness Intervention and Management of Chronic Hepatitis B brand, founded in 2005 (United States), from 496 sister brands and 17477 competing brands. AIM B Avareness Intervention and Management of Chronic Hepatitis B is owned by BRISTOL-MYERS SQUIBB COMPANY, listed on the stock exchange of New York AIM B Avareness Intervention and Management of Chronic Hepatitis B belongs to the Drug Manufacturers business sector.
Investment simulator :
Portfolio valuation
BRISTOL-MYERS SQUIBB COMPANY
(AIM B Avareness Intervention and Management of Chronic Hepatitis B)
over 5 years*
USD 52.96